Our mission at NAVERIS is to deliver innovations in technology with the potential to transform cancer detection, drug development, and clinical trials.

Early detection of malignant cancers is critical to ensuring that tumors can be effectively treated with a favorable prognosis for patients. To this end, we are developing several related technologies with the potential to offer highly sensitive and specific cancer detection through blood analysis. Our flagship technology is a liquid biopsy blood test that analyzes tumor DNA in the circulation to detect specific subtypes of cancer. In clinical studies, this test has established its ability to detect cancers early – in many cases months before patients would be symptomatic given current clinical practice.